Trial halted early: targeted combo tested for tough breast cancer
NCT ID NCT04108858
Summary
This study aimed to see if adding a new drug called copanlisib to standard treatments could better control advanced HER2-positive breast cancer in people with specific genetic changes. It was designed to first find a safe dose and then test if the three-drug combination could keep the cancer from growing longer than the standard two-drug treatment. The trial was terminated early after enrolling only two participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Los Angeles County-USC Medical Center
Los Angeles, California, 90033, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
Conditions
Explore the condition pages connected to this study.